



## BioDelivery Sciences to Host Analyst and Investor Day on February 25th in New York City

January 25, 2016

RALEIGH, N.C., Jan. 25, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host an Analyst and Investor Day on Thursday, February 25<sup>th</sup> from 12:00 PM - 2:30 PM Eastern Time in New York City. The event will focus on both of BDSI's approved products, BUNAVAIL<sup>®</sup> (buprenorphine and naloxone) buccal film (CIII), and BELBUCA<sup>™</sup> (buprenorphine HCl) buccal film (CIII), which is licensed worldwide to Endo Pharmaceuticals. The event will also include an update on the development portfolio, which includes Clonidine Topical Gel for painful diabetic neuropathy and Buprenorphine Depot Injection for both opioid dependence and chronic pain. Both commercial and clinical updates will be provided.

The event will feature Dr. Richard Rauck, President, Carolinas Pain Institute and investigator in the BELBUCA Phase 3 clinical program and Dr. Michael Frost who is President of Frost Medical Group and specializes in the treatment of opioid dependence, as well as several members of the BioDelivery Sciences executive management team.

A live webcast of the event will be available on the BDSI website at [www.bdsi.com](http://www.bdsi.com). The event is intended for institutional investors and sell-side analysts. Please contact Mac MacDonald at 212-915-2567 or via e-mail at [mac@lifesciadvisors.com](mailto:mac@lifesciadvisors.com) for more information.

Richard Rauck, MD, completed his residency in anesthesiology and Fellowship in pain medicine at the University of Cincinnati College of Medicine at Cincinnati, Ohio. Dr. Rauck is board certified in Pain Medicine and Anesthesiology and has been well engaged in clinical research and has an active clinical practice in pain medicine. Dr. Rauck is currently President of the Carolinas Pain Institute and served as an investigator in the Phase 3 clinical development program for BELBUCA and was lead author in the recently published Efficacy and Tolerability of Buprenorphine in Opioid Naïve Patients with Moderate to Severe Chronic Low Back Pain published in *Postgraduate Medicine*, December 2015. Dr. Rauck also serves as President for Sceptor Pain Foundation of which he is a founding member and is immediate past President of World Institute of Pain.

Michael Frost, MD FACP, FASAM, is one of only 1,400 board certified addiction medicine specialists in North America. Dr. Frost completed his residency training at Drexel University College of Pharmacy and is currently President, Frost Medical Group as well as the Medical Director at Eagleville Hospital in Philadelphia. Dr. Frost is also an Assistant Professor of Family, Community and Preventative Medicine at Drexel University College of Medicine. Dr. Frost is actively involved in clinical studies of treatments for opioid dependence.

### **About BioDelivery Sciences International**

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA<sup>®</sup>) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. BDSI's headquarters is located in Raleigh, North Carolina.

For more information, please visit or follow us:

Internet: [www.bdsi.com](http://www.bdsi.com)

Facebook: [Facebook.com/BioDeliverySI](https://www.facebook.com/BioDeliverySI)

Twitter: @BioDeliverySI

**BDSI markets BUNAVAIL<sup>®</sup> (buprenorphine and naloxone) buccal film (CIII) and ONSOLIS<sup>®</sup> (fentanyl buccal soluble film) (CII). BELBUCA<sup>™</sup> (buprenorphine) buccal film (CIII) will be commercialized in the U.S. by Endo Pharmaceuticals pursuant to the worldwide licensing and development agreement between BDSI and Endo. For full prescribing information and important safety information on BDSI products, including BOXED WARNINGS for ONSOLIS and BELBUCA, please visit [www.bdsi.com](http://www.bdsi.com) where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.**

### **Cautionary Note on Forward-Looking Statements**

This press release, the presentation described herein, and any statements of employees, representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto (including, without limitation, at the presentation described herein) contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of clinical trials for the Company's products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements

involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

BDSI<sup>®</sup>, BEMA<sup>®</sup> and BUNAVAIL<sup>®</sup> are registered trademarks of BioDelivery Sciences International, Inc. The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc. All other trademarks and tradenames are owned by their respective owners.

© 2015 BioDelivery Sciences International, Inc. All rights reserved.

Logo - <http://photos.prnewswire.com/prnh/20110217/CL49801LOGO>

SOURCE BioDelivery Sciences International, Inc.

For further information: Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, LLC, 212-915-0685, [matthew@lifesciadvisors.com](mailto:matthew@lifesciadvisors.com); or Al Medwar, Vice President, Marketing and Corporate Development, BioDelivery Sciences International, Inc., 919-582-9050, [amedwar@bdsi.com](mailto:amedwar@bdsi.com); or Media: Susan Forman/Laura Radocaj, Dian Griesel Int'l, 212-825-3210, [sforman@dgicomm.com](mailto:sforman@dgicomm.com), [lradocaj@dgicomm.com](mailto:lradocaj@dgicomm.com)